Biogen ' s Alzheimer ’s Drug Poses a Dilemma for the F.D.A.

If the agency approves it, aducanumab would be the first new Alzheimer ’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works.

Source: NYT Health - June 6, 2021 Category: Consumer Health News Authors: Pam Belluck and Rebecca Robbins Tags: Alzheimer ' s Disease Drugs (Pharmaceuticals) Clinical Trials Aducanumab (drug) Biogen Inc Food and Drug Administration your-feed-science your-feed-healthcare Source Type: news